IDEXX Laboratories (WKN: 888210) IDXX
eröffnet am: | 08.02.18 15:51 von: | Tamakoschy |
neuester Beitrag: | 05.02.24 14:30 von: | Tamakoschy |
Anzahl Beiträge: | 21 | |
Leser gesamt: | 12837 | |
davon Heute: | 13 | |
bewertet mit 0 Sternen |
||
|
08.02.18 15:51
#1
Tamakoschy
IDEXX Laboratories (WKN: 888210) IDXX
http://www.idexx.de/corporate/home.html
https://www.idexx.com/en/about-idexx/investors/
Kurzporträt
Manufactures animal health products
IDEXX Laboratories, Inc. engages in the development, manufacture, and distribution of products and services for the animal veterinary, livestock and poultry, dairy and water testing markets.
It operates through the following business segments: Companion Animal Group; Water; Livestock, Poultry, and Dairy; and Other.
The Companion Animal Group segment refers to diagnostic and information technology-based products and services for the veterinary market.
The Water segment includes water quality products for testing of certain microbiological water contaminants.
The Livestock, Poultry, and Dairy segment involves diagnostic, health-monitoring, and food safety testing products for livestock and poultry health, and dairy products.
The Other segment comprises products for the human point-of-care medical diagnostics market with the company's pharmaceutical product line and out-licensing arrangements.
IDEXX Laboratories was founded by David Evans Shaw on December 19, 1983 and is headquartered in Westbrook, ME.
http://de.4-traders.com/IDEXX-LABORATORIES-9641/...pide&mots=idxx
https://www.idexx.com/en/about-idexx/investors/
Kurzporträt
Manufactures animal health products
IDEXX Laboratories, Inc. engages in the development, manufacture, and distribution of products and services for the animal veterinary, livestock and poultry, dairy and water testing markets.
It operates through the following business segments: Companion Animal Group; Water; Livestock, Poultry, and Dairy; and Other.
The Companion Animal Group segment refers to diagnostic and information technology-based products and services for the veterinary market.
The Water segment includes water quality products for testing of certain microbiological water contaminants.
The Livestock, Poultry, and Dairy segment involves diagnostic, health-monitoring, and food safety testing products for livestock and poultry health, and dairy products.
The Other segment comprises products for the human point-of-care medical diagnostics market with the company's pharmaceutical product line and out-licensing arrangements.
IDEXX Laboratories was founded by David Evans Shaw on December 19, 1983 and is headquartered in Westbrook, ME.
http://de.4-traders.com/IDEXX-LABORATORIES-9641/...pide&mots=idxx
11.11.18 20:03
#2
Tamakoschy
Etwas günstiger
Kurs aktuell etwas zurück gekommen. Immer noch ein interessantes Unternehmen.
https://de.marketscreener.com/IDEXX-LABORATORIES-9641/
Q3
https://www.marketscreener.com/...dexx-3Q-Earnings-Snapshot-27525291/
https://de.marketscreener.com/IDEXX-LABORATORIES-9641/
Q3
https://www.marketscreener.com/...dexx-3Q-Earnings-Snapshot-27525291/
01.02.19 14:41
#3
Tamakoschy
Q4 Zahlen schlage Erwartungen
https://www.marketscreener.com/...dexx-4Q-Earnings-Snapshot-27948600/
https://www.marketscreener.com/...nd-Full-Year-2018-Results-27948509/
02/01/2019 | 06:53am EST
WESTBROOK, Maine (AP) _ Idexx Laboratories Inc. (IDXX) on Friday reported fourth-quarter earnings of $85.6 million.
The Westbrook, Maine-based company said it had net income of 98 cents per share.
The results topped Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for earnings of 90 cents per share.
The Animal diagnostic and health care company posted revenue of $549.4 million in the period, also exceeding Street forecasts. Three analysts surveyed by Zacks expected $545.6 million.
For the year, the company reported profit of $377 million, or $4.26 per share. Revenue was reported as $2.21 billion.
Idexx expects full-year earnings to be $4.66 to $4.78 per share, with revenue in the range of $2.38 billion to $2.42 billion.
https://www.marketscreener.com/...nd-Full-Year-2018-Results-27948509/
02/01/2019 | 06:53am EST
WESTBROOK, Maine (AP) _ Idexx Laboratories Inc. (IDXX) on Friday reported fourth-quarter earnings of $85.6 million.
The Westbrook, Maine-based company said it had net income of 98 cents per share.
The results topped Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for earnings of 90 cents per share.
The Animal diagnostic and health care company posted revenue of $549.4 million in the period, also exceeding Street forecasts. Three analysts surveyed by Zacks expected $545.6 million.
For the year, the company reported profit of $377 million, or $4.26 per share. Revenue was reported as $2.21 billion.
Idexx expects full-year earnings to be $4.66 to $4.78 per share, with revenue in the range of $2.38 billion to $2.42 billion.
01.05.19 16:40
#4
Tamakoschy
q1 wieder über Erwartungen
https://www.marketscreener.com/...dexx-1Q-Earnings-Snapshot-28514373/
05/01/2019 | 06:45am EDT
WESTBROOK, Maine (AP) _ Idexx Laboratories Inc. (IDXX) on Wednesday reported first-quarter earnings of $102.7 million.
On a per-share basis, the Westbrook, Maine-based company said it had net income of $1.17.
The results topped Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for earnings of $1.04 per share.
The Animal diagnostic and health care company posted revenue of $576.1 million in the period.
Idexx expects full-year earnings to be $4.76 to $4.88 per share, with revenue in the range of $2.38 billion to $2.42 billion.
Idexx shares have increased 25% since the beginning of the year. The stock has risen 19% in the last 12 months.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on IDXX at https://www.zacks.com/ap/IDXX
Automated Insights, source Associated Press News
05/01/2019 | 06:45am EDT
WESTBROOK, Maine (AP) _ Idexx Laboratories Inc. (IDXX) on Wednesday reported first-quarter earnings of $102.7 million.
On a per-share basis, the Westbrook, Maine-based company said it had net income of $1.17.
The results topped Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for earnings of $1.04 per share.
The Animal diagnostic and health care company posted revenue of $576.1 million in the period.
Idexx expects full-year earnings to be $4.76 to $4.88 per share, with revenue in the range of $2.38 billion to $2.42 billion.
Idexx shares have increased 25% since the beginning of the year. The stock has risen 19% in the last 12 months.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on IDXX at https://www.zacks.com/ap/IDXX
Automated Insights, source Associated Press News
31.10.19 18:07
#5
Tamakoschy
Q3 Über Erwartungen
https://www.marketscreener.com/...ondition-and-Results-of-O-29492368/
https://www.marketscreener.com/...dexx-3Q-Earnings-Snapshot-29489583/
Idexx: 3Q Earnings Snapshot
10/31/2019 | 06:46am EDT
WESTBROOK, Maine (AP) _ Idexx Laboratories Inc. (IDXX) on Thursday reported third-quarter net income of $108.8 million.
The Westbrook, Maine-based company said it had net income of $1.24 per share.
The results surpassed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for earnings of $1.13 per share.
The Animal diagnostic and health care company posted revenue of $605.3 million in the period, also exceeding Street forecasts. Three analysts surveyed by Zacks expected $597.4 million.
Idexx expects full-year earnings to be $4.72 to $4.78 per share, with revenue expected to be $2.4 billion.
Idexx shares have risen 47% since the beginning of the year. The stock has climbed 30% in the last 12 months.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on IDXX at https://www.zacks.com/ap/IDXX
Automated Insights, source Associated Press News
https://www.marketscreener.com/...dexx-3Q-Earnings-Snapshot-29489583/
Idexx: 3Q Earnings Snapshot
10/31/2019 | 06:46am EDT
WESTBROOK, Maine (AP) _ Idexx Laboratories Inc. (IDXX) on Thursday reported third-quarter net income of $108.8 million.
The Westbrook, Maine-based company said it had net income of $1.24 per share.
The results surpassed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for earnings of $1.13 per share.
The Animal diagnostic and health care company posted revenue of $605.3 million in the period, also exceeding Street forecasts. Three analysts surveyed by Zacks expected $597.4 million.
Idexx expects full-year earnings to be $4.72 to $4.78 per share, with revenue expected to be $2.4 billion.
Idexx shares have risen 47% since the beginning of the year. The stock has climbed 30% in the last 12 months.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on IDXX at https://www.zacks.com/ap/IDXX
Automated Insights, source Associated Press News
02.02.20 16:01
#6
Tamakoschy
Q4 über Erwartungen - Kurs hat trotzdem Schnupfen
https://www.marketscreener.com/...dexx-4Q-Earnings-Snapshot-29920185/
Idexx: 4Q Earnings Snapshot
01/31/2020 | 06:59am EST
WESTBROOK, Maine (AP) _ Idexx Laboratories Inc. (IDXX) on Friday reported fourth-quarter earnings of $90.5 million.
On a per-share basis, the Westbrook, Maine-based company said it had profit of $1.04.
The results beat Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for earnings of 91 cents per share.
The Animal diagnostic and health care company posted revenue of $605.4 million in the period, which also beat Street forecasts. Three analysts surveyed by Zacks expected $599.9 million.
For the year, the company reported profit of $427.7 million, or $4.89 per share. Revenue was reported as $2.41 billion.
Idexx expects full-year earnings to be $5.42 to $5.58 per share, with revenue in the range of $2.62 billion to $2.66 billion.
Idexx shares have risen roughly 9% since the beginning of the year. The stock has increased 37% in the last 12 months.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on IDXX at https://www.zacks.com/ap/IDXX
Automated Insights, source Associated Press News
https://www.marketscreener.com/...nd-Full-Year-2019-Results-29920019/
Achieves revenue growth in Q4 of 10% on a reported and organic basis, driven by CAG Diagnostics recurring revenue reported and organic growth of 11%
Reports 19% year-over-year increase in Catalyst placements at new and competitive accounts in Q4, supporting full year growth of 16% in IDEXX's premium instrument installed base
Delivers full year EPS of $4.89, representing 15% growth on a reported basis and 21% on a comparable constant currency basis
Increases 2020 revenue guidance to $2,620 million - $2,655 million, reflecting consistent expectations for reported and organic revenue growth of 9% - 10.5%
Raises 2020 EPS outlook range by $0.12 to $5.42 - $5.58, reflecting expectations for continued strong operating trends, higher estimates for share-based compensation tax benefits and favorable adjustments to projected foreign exchange rates impacts
Idexx: 4Q Earnings Snapshot
01/31/2020 | 06:59am EST
WESTBROOK, Maine (AP) _ Idexx Laboratories Inc. (IDXX) on Friday reported fourth-quarter earnings of $90.5 million.
On a per-share basis, the Westbrook, Maine-based company said it had profit of $1.04.
The results beat Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for earnings of 91 cents per share.
The Animal diagnostic and health care company posted revenue of $605.4 million in the period, which also beat Street forecasts. Three analysts surveyed by Zacks expected $599.9 million.
For the year, the company reported profit of $427.7 million, or $4.89 per share. Revenue was reported as $2.41 billion.
Idexx expects full-year earnings to be $5.42 to $5.58 per share, with revenue in the range of $2.62 billion to $2.66 billion.
Idexx shares have risen roughly 9% since the beginning of the year. The stock has increased 37% in the last 12 months.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on IDXX at https://www.zacks.com/ap/IDXX
Automated Insights, source Associated Press News
https://www.marketscreener.com/...nd-Full-Year-2019-Results-29920019/
Achieves revenue growth in Q4 of 10% on a reported and organic basis, driven by CAG Diagnostics recurring revenue reported and organic growth of 11%
Reports 19% year-over-year increase in Catalyst placements at new and competitive accounts in Q4, supporting full year growth of 16% in IDEXX's premium instrument installed base
Delivers full year EPS of $4.89, representing 15% growth on a reported basis and 21% on a comparable constant currency basis
Increases 2020 revenue guidance to $2,620 million - $2,655 million, reflecting consistent expectations for reported and organic revenue growth of 9% - 10.5%
Raises 2020 EPS outlook range by $0.12 to $5.42 - $5.58, reflecting expectations for continued strong operating trends, higher estimates for share-based compensation tax benefits and favorable adjustments to projected foreign exchange rates impacts
06.05.20 21:17
#7
Tamakoschy
Q1 2020
https://www.marketscreener.com/...dexx-1Q-Earnings-Snapshot-30502962/
Idexx: 1Q Earnings Snapshot
share with twitter share with LinkedIn share with facebook share via e-mail
0
04/30/2020 | 11:45am BST
WESTBROOK, Maine (AP) _ Idexx Laboratories Inc. (IDXX) on Thursday reported first-quarter profit of $111.8 million.
On a per-share basis, the Westbrook, Maine-based company said it had profit of $1.29.
The results beat Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for earnings of $1.23 per share.
The Animal diagnostic and health care company posted revenue of $626.3 million in the period, missing Street forecasts. Three analysts surveyed by Zacks expected $631.8 million.
Idexx shares have risen slightly more than 4% since the beginning of the year. The stock has climbed 18% in the last 12 months.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on IDXX at https://www.zacks.com/ap/IDXX
Automated Insights, source Associated Press News
Idexx: 1Q Earnings Snapshot
share with twitter share with LinkedIn share with facebook share via e-mail
0
04/30/2020 | 11:45am BST
WESTBROOK, Maine (AP) _ Idexx Laboratories Inc. (IDXX) on Thursday reported first-quarter profit of $111.8 million.
On a per-share basis, the Westbrook, Maine-based company said it had profit of $1.29.
The results beat Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for earnings of $1.23 per share.
The Animal diagnostic and health care company posted revenue of $626.3 million in the period, missing Street forecasts. Three analysts surveyed by Zacks expected $631.8 million.
Idexx shares have risen slightly more than 4% since the beginning of the year. The stock has climbed 18% in the last 12 months.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on IDXX at https://www.zacks.com/ap/IDXX
Automated Insights, source Associated Press News
01.08.20 17:40
#8
Tamakoschy
Q2 Gute Zahlen
https://www.marketscreener.com/...dexx-2Q-Earnings-Snapshot-31029808/
dexx: 2Q Earnings Snapshot
07/31/2020 | 11:42am BST
WESTBROOK, Maine (AP) _ Idexx Laboratories Inc. (IDXX) on Friday reported second-quarter profit of $148.9 million.
On a per-share basis, the Westbrook, Maine-based company said it had profit of $1.72.
The results surpassed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for earnings of $1.20 per share.
The Animal diagnostic and health care company posted revenue of $637.6 million in the period, also exceeding Street forecasts. Three analysts surveyed by Zacks expected $580 million.
Idexx shares have risen 43% since the beginning of the year. The stock has risen 31% in the last 12 months.
dexx: 2Q Earnings Snapshot
07/31/2020 | 11:42am BST
WESTBROOK, Maine (AP) _ Idexx Laboratories Inc. (IDXX) on Friday reported second-quarter profit of $148.9 million.
On a per-share basis, the Westbrook, Maine-based company said it had profit of $1.72.
The results surpassed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for earnings of $1.20 per share.
The Animal diagnostic and health care company posted revenue of $637.6 million in the period, also exceeding Street forecasts. Three analysts surveyed by Zacks expected $580 million.
Idexx shares have risen 43% since the beginning of the year. The stock has risen 31% in the last 12 months.
29.10.20 14:33
#9
Tamakoschy
Q3 Erwartungen übertroffen
https://www.marketscreener.com/quote/stock/...ings-Snapshot-31639779/
Idexx: 3Q Earnings Snapshot
10/29/2020 | 10:51am GMT
WESTBROOK, Maine (AP) _ Idexx Laboratories Inc. (IDXX) on Thursday reported third-quarter profit of $146.2 million.
On a per-share basis, the Westbrook, Maine-based company said it had profit of $1.69.
The results topped Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for earnings of $1.42 per share.
The Animal diagnostic and health care company posted revenue of $721.8 million in the period, which also beat Street forecasts. Three analysts surveyed by Zacks expected $670.7 million.
Idexx shares have risen 62% since the beginning of the year. The stock has increased 59% in the last 12 months.
Idexx: 3Q Earnings Snapshot
10/29/2020 | 10:51am GMT
WESTBROOK, Maine (AP) _ Idexx Laboratories Inc. (IDXX) on Thursday reported third-quarter profit of $146.2 million.
On a per-share basis, the Westbrook, Maine-based company said it had profit of $1.69.
The results topped Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for earnings of $1.42 per share.
The Animal diagnostic and health care company posted revenue of $721.8 million in the period, which also beat Street forecasts. Three analysts surveyed by Zacks expected $670.7 million.
Idexx shares have risen 62% since the beginning of the year. The stock has increased 59% in the last 12 months.
29.10.20 14:45
#10
Tamakoschy
Q 3 Nachtrag
https://www.marketscreener.com/quote/stock/...arter-Results-31639565/
Achieves revenue growth of 19% on a reported basis and 18% on an organic basis driven by Companion Animal Group Diagnostics recurring revenue growth of 23% reported and 21% organic
High revenue growth supported by sustained strong global recovery in the pet healthcare market
Delivers EPS of $1.69, representing 36% growth on a reported basis and 47% on a comparable constant currency basis, reflecting benefits from high CAG Diagnostics recurring revenue gains and proactive cost controls
Achieves revenue growth of 19% on a reported basis and 18% on an organic basis driven by Companion Animal Group Diagnostics recurring revenue growth of 23% reported and 21% organic
High revenue growth supported by sustained strong global recovery in the pet healthcare market
Delivers EPS of $1.69, representing 36% growth on a reported basis and 47% on a comparable constant currency basis, reflecting benefits from high CAG Diagnostics recurring revenue gains and proactive cost controls
02.02.21 16:49
#11
Tamakoschy
Q4 Top Zahlen - neues ATH
https://www.marketscreener.com/quote/stock/...ings-Snapshot-32334711/
4Q Earnings Snapshot
02/02/2021 | 11:49am GMT
WESTBROOK, Maine (AP) _ Idexx Laboratories Inc. (IDXX) on Tuesday reported fourth-quarter earnings of $174.8 million.
The Westbrook, Maine-based company said it had net income of $2.01 per share.
The results beat Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for earnings of $1.43 per share.
The Animal diagnostic and health care company posted revenue of $720.9 million in the period, which also topped Street forecasts. Four analysts surveyed by Zacks expected $681.5 million.
For the year, the company reported profit of $581.8 million, or $6.71 per share. Revenue was reported as $2.71 billion.
Idexx expects full-year earnings to be $7.39 to $7.71 per share, with revenue in the range of $3.07 billion to $3.12 billion.
Idexx shares have decreased 1.5% since the beginning of the year. The stock has risen 74% in the last 12 months.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on IDXX at https://www.zacks.com/ap/IDXX
Copyright by Automated Insights, Inc. All rights reserved., source Associated Press News
https://www.marketscreener.com/quote/stock/...-2021-Outlook-32335507/
4Q Earnings Snapshot
02/02/2021 | 11:49am GMT
WESTBROOK, Maine (AP) _ Idexx Laboratories Inc. (IDXX) on Tuesday reported fourth-quarter earnings of $174.8 million.
The Westbrook, Maine-based company said it had net income of $2.01 per share.
The results beat Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for earnings of $1.43 per share.
The Animal diagnostic and health care company posted revenue of $720.9 million in the period, which also topped Street forecasts. Four analysts surveyed by Zacks expected $681.5 million.
For the year, the company reported profit of $581.8 million, or $6.71 per share. Revenue was reported as $2.71 billion.
Idexx expects full-year earnings to be $7.39 to $7.71 per share, with revenue in the range of $3.07 billion to $3.12 billion.
Idexx shares have decreased 1.5% since the beginning of the year. The stock has risen 74% in the last 12 months.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on IDXX at https://www.zacks.com/ap/IDXX
Copyright by Automated Insights, Inc. All rights reserved., source Associated Press News
https://www.marketscreener.com/quote/stock/...-2021-Outlook-32335507/
26.02.21 21:25
#12
Naim1000
IDEXX
Bin jetzt auch dabei. Die Growth Story stimmt und mich hat der hohe Anteil an wiederkehrenden Umsätzen überzeugt. Da ich 3-5 Jahre Zeit mitbringe, ist das Investment ein No-Brainer
01.08.21 11:02
#13
Tamakoschy
Q2 Zahlen über Erwartungen
https://www.marketscreener.com/quote/stock/...ings-Snapshot-36016661/
Idexx: Q2 Earnings Snapshot
07/30/2021 | 11:41am BST
WESTBROOK, Maine (AP) _ Idexx Laboratories Inc. (IDXX) on Friday reported second-quarter profit of $202.6 million.
On a per-share basis, the Westbrook, Maine-based company said it had profit of $2.34.
The results exceeded Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for earnings of $2.01 per share.
The Animal diagnostic and health care company posted revenue of $826.1 million in the period, also exceeding Street forecasts. Four analysts surveyed by Zacks expected $781.5 million.
Idexx expects full-year earnings to be $8.20 to $8.36 per share, with revenue in the range of $3.17 billion to $3.21 billion.
Idexx shares have climbed 41% since the beginning of the year. The stock has increased 92% in the last 12 months.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on IDXX at https://www.zacks.com/ap/IDXX
Copyright by Automated Insights, Inc. All rights reserved., source Associated Press News
https://www.marketscreener.com/quote/stock/...-Results-of-O-36023448/
Idexx: Q2 Earnings Snapshot
07/30/2021 | 11:41am BST
WESTBROOK, Maine (AP) _ Idexx Laboratories Inc. (IDXX) on Friday reported second-quarter profit of $202.6 million.
On a per-share basis, the Westbrook, Maine-based company said it had profit of $2.34.
The results exceeded Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for earnings of $2.01 per share.
The Animal diagnostic and health care company posted revenue of $826.1 million in the period, also exceeding Street forecasts. Four analysts surveyed by Zacks expected $781.5 million.
Idexx expects full-year earnings to be $8.20 to $8.36 per share, with revenue in the range of $3.17 billion to $3.21 billion.
Idexx shares have climbed 41% since the beginning of the year. The stock has increased 92% in the last 12 months.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on IDXX at https://www.zacks.com/ap/IDXX
Copyright by Automated Insights, Inc. All rights reserved., source Associated Press News
https://www.marketscreener.com/quote/stock/...-Results-of-O-36023448/
02.02.22 18:56
#14
neymar
IDEXX
IDEXX Laboratories And Its Real Value
https://seekingalpha.com/article/...x-laboratories-and-its-real-value
https://seekingalpha.com/article/...x-laboratories-and-its-real-value
02.02.22 18:58
#15
Tamakoschy
Q4 über Erwartungen
IDEXX Laboratories steigert Gewinn und Umsatz im 4. Quartal und gibt Prognose für 2022 ab
02.02.2022 | 13:12
(MT Newswires) -- IDEXX Laboratories (IDXX) meldete am Mittwoch für das vierte Quartal einen Gewinn pro Aktie von $1,83, verglichen mit $1,63 im Vorjahr.
Die von Capital IQ befragten Analysten erwarteten $1,72.
Der Umsatz von $801,1 Millionen lag über dem Vorjahreswert von $720,9 Millionen. Die von Capital IQ befragten Analysten hatten mit 781,8 Mio. $ gerechnet.
Für das Jahr 2022 erwartet das Unternehmen einen Gewinn je Aktie zwischen 9,27 und 9,59 Dollar bei einem Umsatz von 3,5 bis 3,6 Milliarden Dollar.
https://de.marketscreener.com/kurs/aktie/...ose-fur-2022-ab-37720598/
IDEXX Laboratories steigert Gewinn und Umsatz im 4. Quartal und gibt Prognose für 2022 ab
02.02.2022 | 13:12
(MT Newswires) -- IDEXX Laboratories (IDXX) meldete am Mittwoch für das vierte Quartal einen Gewinn pro Aktie von $1,83, verglichen mit $1,63 im Vorjahr.
Die von Capital IQ befragten Analysten erwarteten $1,72.
Der Umsatz von $801,1 Millionen lag über dem Vorjahreswert von $720,9 Millionen. Die von Capital IQ befragten Analysten hatten mit 781,8 Mio. $ gerechnet.
Für das Jahr 2022 erwartet das Unternehmen einen Gewinn je Aktie zwischen 9,27 und 9,59 Dollar bei einem Umsatz von 3,5 bis 3,6 Milliarden Dollar.
https://de.marketscreener.com/kurs/aktie/...ose-fur-2022-ab-37720598/
04.05.22 18:41
#16
Tamakoschy
Q1 und Ausblick schwach
IDEXX Laboratories Q1 Gewinnrückgang, Umsatzanstieg; Unternehmen senkt Ausblick für 2022
04.05.2022 | 13:20
(MT Newswires) -- IDEXX Laboratories (IDXX) meldete am Mittwoch für das erste Quartal einen Gewinn von $2,27 pro verwässerter Aktie, gegenüber $2,35 im Vorjahr.
Die von Capital IQ befragten Analysten hatten mit $2,24 gerechnet.
Der Umsatz für das Quartal, das am 31. März endete, lag bei 836,5 Mio. $, gegenüber 777,7 Mio. $ im Vorjahresquartal.
Die von Capital IQ befragten Analysten hatten $836,5 Millionen prognostiziert.
Für das Gesamtjahr 2022 rechnet das Tiergesundheitsunternehmen nun mit einem Gewinn je Aktie von 8,11 bis 8,35 Dollar, nachdem zuvor 9,27 bis 9,59 Dollar erwartet worden waren.
IDEXX rechnet für das Jahr 2022 mit einem Umsatz von 3,39 bis 3,47 Mrd. Dollar, nachdem zuvor 3,5 bis 3,57 Mrd. Dollar erwartet wurden.
Die Aktien des Unternehmens gaben im vorbörslichen Handel um 9% nach.
Kurs: 396.75, Veränderung: -39.21, Prozentuale Veränderung: -8.99
04.05.2022 | 13:20
(MT Newswires) -- IDEXX Laboratories (IDXX) meldete am Mittwoch für das erste Quartal einen Gewinn von $2,27 pro verwässerter Aktie, gegenüber $2,35 im Vorjahr.
Die von Capital IQ befragten Analysten hatten mit $2,24 gerechnet.
Der Umsatz für das Quartal, das am 31. März endete, lag bei 836,5 Mio. $, gegenüber 777,7 Mio. $ im Vorjahresquartal.
Die von Capital IQ befragten Analysten hatten $836,5 Millionen prognostiziert.
Für das Gesamtjahr 2022 rechnet das Tiergesundheitsunternehmen nun mit einem Gewinn je Aktie von 8,11 bis 8,35 Dollar, nachdem zuvor 9,27 bis 9,59 Dollar erwartet worden waren.
IDEXX rechnet für das Jahr 2022 mit einem Umsatz von 3,39 bis 3,47 Mrd. Dollar, nachdem zuvor 3,5 bis 3,57 Mrd. Dollar erwartet wurden.
Die Aktien des Unternehmens gaben im vorbörslichen Handel um 9% nach.
Kurs: 396.75, Veränderung: -39.21, Prozentuale Veränderung: -8.99
01.11.22 15:33
#17
Tamakoschy
Q3 Über Erwartungen
IDEXX Laboratories Q3 EPS, Umsatzanstieg; senkt EPS-Prognose für 2022
01.11.2022 | 12:30
(MT Newswires) -- IDEXX Laboratories (IDXX) meldete am Dienstag für das 3. Quartal einen Gewinn von $2,15 je verwässerter Aktie, gegenüber $2,03 im Vorjahr.
Die von Capital IQ befragten Analysten hatten $2,04 erwartet.
Der Umsatz für das Quartal, das am 30. September endete, lag bei 841,7 Millionen Dollar, verglichen mit 810,4 Millionen Dollar im Vorjahr.
Die von Capital IQ befragten Analysten hatten mit $830 Millionen gerechnet.
Für das Gesamtjahr 2022 rechnet das Unternehmen nun mit einem Gewinn je Aktie von 7,74 bis 7,98 Dollar. Dies steht im Vergleich zu der vorherigen Prognose von $7,77 bis $8,05.
Außerdem erwartet das Unternehmen für 2022 einen Umsatz von 3,33 bis 3,37 Milliarden Dollar. Zuvor waren es 3,31 bis 3,39 Milliarden Dollar.
https://de.marketscreener.com/kurs/aktie/...ognose-fur-2022-42164675/
01.11.2022 | 12:30
(MT Newswires) -- IDEXX Laboratories (IDXX) meldete am Dienstag für das 3. Quartal einen Gewinn von $2,15 je verwässerter Aktie, gegenüber $2,03 im Vorjahr.
Die von Capital IQ befragten Analysten hatten $2,04 erwartet.
Der Umsatz für das Quartal, das am 30. September endete, lag bei 841,7 Millionen Dollar, verglichen mit 810,4 Millionen Dollar im Vorjahr.
Die von Capital IQ befragten Analysten hatten mit $830 Millionen gerechnet.
Für das Gesamtjahr 2022 rechnet das Unternehmen nun mit einem Gewinn je Aktie von 7,74 bis 7,98 Dollar. Dies steht im Vergleich zu der vorherigen Prognose von $7,77 bis $8,05.
Außerdem erwartet das Unternehmen für 2022 einen Umsatz von 3,33 bis 3,37 Milliarden Dollar. Zuvor waren es 3,31 bis 3,39 Milliarden Dollar.
https://de.marketscreener.com/kurs/aktie/...ognose-fur-2022-42164675/
06.02.23 18:16
#18
Tamakoschy
Q4 über Erwartungen
https://de.marketscreener.com/kurs/aktie/...d-Umsatzanstieg-42908837/
IDEXX Laboratories: Q4-Ergebnis und Umsatzanstieg
(MT Newswires) -- IDEXX Laboratories (IDXX) meldete am Montag für das vierte Quartal einen bereinigten Gewinn von $2,07 je verwässerter Aktie, nach $1,81 im Vorjahr.
Die von Capital IQ befragten Analysten hatten mit $1,92 gerechnet.
Der Umsatz für das Quartal, das am 31. Dezember endete, belief sich auf 828,6 Millionen Dollar, verglichen mit 801,1 Millionen Dollar vor einem Jahr.
Die von Capital IQ befragten Analysten hatten $ 820,9 Millionen erwartet.
Das Unternehmen sagte, es erwarte für das Gesamtjahr 2023 einen Gewinn von 9,27 bis 9,75 Dollar je verwässerter Aktie. Die von Capital IQ befragten Analysten erwarten $9,47.
Das Unternehmen erwartet für das Jahr einen Umsatz von 3,60 bis 3,69 Milliarden Dollar. Die von Capital IQ befragten Analysten rechnen mit $3,62 Milliarden.
IDEXX Laboratories: Q4-Ergebnis und Umsatzanstieg
(MT Newswires) -- IDEXX Laboratories (IDXX) meldete am Montag für das vierte Quartal einen bereinigten Gewinn von $2,07 je verwässerter Aktie, nach $1,81 im Vorjahr.
Die von Capital IQ befragten Analysten hatten mit $1,92 gerechnet.
Der Umsatz für das Quartal, das am 31. Dezember endete, belief sich auf 828,6 Millionen Dollar, verglichen mit 801,1 Millionen Dollar vor einem Jahr.
Die von Capital IQ befragten Analysten hatten $ 820,9 Millionen erwartet.
Das Unternehmen sagte, es erwarte für das Gesamtjahr 2023 einen Gewinn von 9,27 bis 9,75 Dollar je verwässerter Aktie. Die von Capital IQ befragten Analysten erwarten $9,47.
Das Unternehmen erwartet für das Jahr einen Umsatz von 3,60 bis 3,69 Milliarden Dollar. Die von Capital IQ befragten Analysten rechnen mit $3,62 Milliarden.
02.05.23 18:28
#19
Tamakoschy
Q1
https://de.marketscreener.com/kurs/aktie/...n-Umsatzanstieg-43711603/
IDEXX Laboratories Q1 bereinigter Gewinn, Umsatzanstieg
02.05.2023 | 14:05
(MT Newswires) -- IDEXX Laboratories (IDXX) meldete am Dienstag für das erste Quartal einen Gewinn von 2,55 Dollar pro verwässerter Aktie, nach 2,27 Dollar pro Aktie vor einem Jahr.
Die von Capital IQ befragten Analysten hatten ein EPS von $2,38 erwartet.
Der Umsatz für das Quartal, das am 31. März endete, betrug 900,2 Millionen Dollar, verglichen mit 836,5 Millionen Dollar vor einem Jahr. Die von Capital IQ befragten Analysten hatten $890,6 Millionen erwartet.
Das Unternehmen sagte, es erwarte 2023 ein EPS von $9,33 bis $9,75. Die von Capital IQ befragten Analysten erwarten $9,48. Der Umsatz für das Jahr wird voraussichtlich zwischen $3,62 Milliarden und $3,70 Milliarden liegen. Die von Capital IQ befragten Analysten erwarten $3,66 Milliarden.
IDEXX Laboratories Q1 bereinigter Gewinn, Umsatzanstieg
02.05.2023 | 14:05
(MT Newswires) -- IDEXX Laboratories (IDXX) meldete am Dienstag für das erste Quartal einen Gewinn von 2,55 Dollar pro verwässerter Aktie, nach 2,27 Dollar pro Aktie vor einem Jahr.
Die von Capital IQ befragten Analysten hatten ein EPS von $2,38 erwartet.
Der Umsatz für das Quartal, das am 31. März endete, betrug 900,2 Millionen Dollar, verglichen mit 836,5 Millionen Dollar vor einem Jahr. Die von Capital IQ befragten Analysten hatten $890,6 Millionen erwartet.
Das Unternehmen sagte, es erwarte 2023 ein EPS von $9,33 bis $9,75. Die von Capital IQ befragten Analysten erwarten $9,48. Der Umsatz für das Jahr wird voraussichtlich zwischen $3,62 Milliarden und $3,70 Milliarden liegen. Die von Capital IQ befragten Analysten erwarten $3,66 Milliarden.
01.11.23 15:19
#20
Tamakoschy
Q3
https://de.marketscreener.com/kurs/aktie/...se-2023-gesenkt-45209388/
IDEXX Laboratories Q3 vergleichbares Ergebnis, Umsatzanstieg; Umsatzprognose 2023 gesenkt
Am 01. November 2023 um 12:21 Uhr
(MT Newswires) -- IDEXX Laboratories (IDXX) meldete am Mittwoch für das 3. Quartal einen vergleichbaren Gewinn von $2,50 pro Aktie, gegenüber $2,15 im Vorjahr.
Die von Capital IQ befragten Analysten hatten $2,37 erwartet.
Der Umsatz für das Quartal, das am 30. September endete, betrug 915,5 Millionen Dollar, verglichen mit 841,7 Millionen Dollar im Vorjahr.
Die von Capital IQ befragten Analysten hatten 927,3 Millionen Dollar erwartet.
Für das Jahr 2023 rechnet das Unternehmen für Haustiermedizin nun mit einem Gewinn je Aktie von 9,74 bis 9,90 Dollar, nachdem zuvor 9,64 bis 9,90 Dollar erwartet worden waren. Die von Capital IQ befragten Analysten rechnen mit $9,78. Das Unternehmen rechnet nun mit einem Umsatz von 3,64 bis 3,65 Mrd. $, nachdem es zuvor eine Spanne von 3,66 bis 3,72 Mrd. $ angekündigt hatte. Die von Capital IQ befragten Analysten rechnen mit $3,68 Milliarden.
IDEXX Laboratories Q3 vergleichbares Ergebnis, Umsatzanstieg; Umsatzprognose 2023 gesenkt
Am 01. November 2023 um 12:21 Uhr
(MT Newswires) -- IDEXX Laboratories (IDXX) meldete am Mittwoch für das 3. Quartal einen vergleichbaren Gewinn von $2,50 pro Aktie, gegenüber $2,15 im Vorjahr.
Die von Capital IQ befragten Analysten hatten $2,37 erwartet.
Der Umsatz für das Quartal, das am 30. September endete, betrug 915,5 Millionen Dollar, verglichen mit 841,7 Millionen Dollar im Vorjahr.
Die von Capital IQ befragten Analysten hatten 927,3 Millionen Dollar erwartet.
Für das Jahr 2023 rechnet das Unternehmen für Haustiermedizin nun mit einem Gewinn je Aktie von 9,74 bis 9,90 Dollar, nachdem zuvor 9,64 bis 9,90 Dollar erwartet worden waren. Die von Capital IQ befragten Analysten rechnen mit $9,78. Das Unternehmen rechnet nun mit einem Umsatz von 3,64 bis 3,65 Mrd. $, nachdem es zuvor eine Spanne von 3,66 bis 3,72 Mrd. $ angekündigt hatte. Die von Capital IQ befragten Analysten rechnen mit $3,68 Milliarden.
05.02.24 14:30
#21
Tamakoschy
Q4 über Erwartungen - Wachstum intakt
https://de.marketscreener.com/kurs/aktie/...n-Umsatzanstieg-45883604/
IDEXX Laboratories: Q4-Gewinn, Umsatzanstieg
Am 05. Februar 2024 um 13:22 Uhr
(MT Newswires) -- IDEXX Laboratories (IDXX) meldete am Montag für das vierte Quartal einen Gewinn von $2,32 pro verwässerter Aktie, gegenüber $2,05 im Vorjahr.
Die von Capital IQ befragten Analysten hatten $2,12 erwartet.
Der Umsatz für das Quartal, das am 31. Dezember endete, betrug 901,6 Millionen Dollar, verglichen mit 828,6 Millionen Dollar im Vorjahr.
Die von Capital IQ befragten Analysten hatten mit $890,6 Millionen gerechnet.
Das Unternehmen sagte, es erwarte 2024 einen Gewinn von 10,84 bis 11,33 Dollar pro Aktie bei einem Umsatz von 3,93 bis 4,04 Milliarden Dollar. Die von Capital IQ befragten Analysten erwarten einen Gewinn von $10,93 pro Aktie bei einem Umsatz von $3,97 Milliarden.
IDEXX Laboratories: Q4-Gewinn, Umsatzanstieg
Am 05. Februar 2024 um 13:22 Uhr
(MT Newswires) -- IDEXX Laboratories (IDXX) meldete am Montag für das vierte Quartal einen Gewinn von $2,32 pro verwässerter Aktie, gegenüber $2,05 im Vorjahr.
Die von Capital IQ befragten Analysten hatten $2,12 erwartet.
Der Umsatz für das Quartal, das am 31. Dezember endete, betrug 901,6 Millionen Dollar, verglichen mit 828,6 Millionen Dollar im Vorjahr.
Die von Capital IQ befragten Analysten hatten mit $890,6 Millionen gerechnet.
Das Unternehmen sagte, es erwarte 2024 einen Gewinn von 10,84 bis 11,33 Dollar pro Aktie bei einem Umsatz von 3,93 bis 4,04 Milliarden Dollar. Die von Capital IQ befragten Analysten erwarten einen Gewinn von $10,93 pro Aktie bei einem Umsatz von $3,97 Milliarden.